Or­chard sets US price tag for rare dis­ease gene ther­a­py Len­meldy at $4.25M

Or­chard Ther­a­peu­tics’ ul­tra-rare dis­ease drug Len­meldy is vault­ing to the list of most ex­pen­sive drugs ever with a whole­sale ac­qui­si­tion cost of $4.25 mil­lion for …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.